



ASX ANNOUNCEMENT

19 December 2019

## **CardieX Announces Major New Clinical Trial Services Contract with Global Pharmaceutical Company Bayer AG.**

**CardieX Limited (ASX: CDX) (CardieX, the Company)** announces it's 100% subsidiary ATCOR has entered into a significant new contract with global pharmaceutical company Bayer AG for the provision of clinical trial services utilizing ATCOR technology and data management services.

### **Highlights:**

- **Agreement provides for the provision of both ATCOR equipment as well as trial data management services over a period of 15 months commencing April, 2020 for a study being conducted by German global pharmaceutical and life sciences company, Bayer AG.**
- **Study will utilize both ATCOR's XCEL device as well as OSCAR 2 – a 24-hour ambulatory device powered by ATCOR's SphygmoCor® technology.**
- **Total new revenue recognition to CardieX of \$US1.275M over a 15 month period (approximately \$AUD1.9M).**
- **Study to cover upwards of 50 sites in both the EU and USA.**

Bayer AG is one of the most recognizable multinational pharmaceutical and life sciences companies in the world and are global leaders in the advancement of science innovation, research and development, providing products and services to millions of patients and consumers across areas of pharma, biotechnology and therapeutic treatments in oncology, cardiology and hematology.

**Craig Cooper, CEO of CardieX commented:** *This new contract with major pharmaceutical and life sciences company Bayer AG is further recognition of the global importance of our technology for the diagnosis and monitoring of vascular disease. Over the last 12 months we have accelerated the focus and marketing efforts of our clinical trial services group and these efforts are beginning to show in both new contracts and also in our pipeline of new business development.*

*Whereas previous contracts have focused on cardiovascular trials, we are now actively expanding our marketing efforts to cover a wider range of clinical trials that need monitoring of vascular health, such as diabetes, Alzheimer's and related disorders. We expect this clinical trial services group to contribute significantly to our group revenues going forward".*



For more information please contact:

**CardieX Investor Relations: Peter Taylor**

[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)

### **About Bayer AG**

Bayer AG is a multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Headquartered in Germany, Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index.

### **About CardieX**

CardieX is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019 CardieX signed a joint development agreement with Mobvoi Information Technology Co. Ltd (Google's official Wear OS partner in China) to jointly develop an ecosystem of "smart heart" and other consumer health applications for the Google Wear OS platform in China based on CardieX subsidiary, ATCOR, software and algorithms.